Back

High potency statins and beyond: benefits of combination therapy.

29 August 2017 (12:55 - 13:10)
Organised by:
Congress Presentation Part of: Are we prepared to reduce LDL-cholesterol at any cost? Drug therapy Open Access ESC Congress 2017

About the speaker

Photo
Doctor Michel Farnier

University of Bourgogne Franche Comte, Dijon (France)

4 More presentations in this session

Presentation thumbnail
Challenges for reaching LDL-C goals in high and very high risk patients.
Professor L. Tokgozoglu (Ankara, TR)
Presentation thumbnail
Last step on the ladder: proprotein convertase subtilisin/kexin type 9 (PCSK9).
Professor L. Tokgozoglu (Ankara, TR)
Presentation thumbnail
Cost implications of misunderstanding statin intolerance.
Professor E. Stroes (Amsterdam, NL)
Presentation thumbnail
Conclusion - Are we prepared to reduce LDL-cholesterol at any cost?
Professor L. Tokgozoglu (Ankara, TR)

Access the full session

Session thumbnail
Are we prepared to reduce LDL-cholesterol at any cost?

The Event

Event poster

ESC Congress 2017

29 August 2017 12:55 CET
You may be interested in
thumbnail
Congress Presentation
Forging the path: strategic combinations to achieve lipid targets
29 August 2025
thumbnail
Congress Presentation
Combination therapy rapidly improves symptoms and quality of life in recently diagnosed angina patients: the COMBINE Angina study
1 September 2025
thumbnail
Congress Session
Innovative drug therapies in heart failure
18 May 2025
thumbnail
Webinar
Reducing risk in the post-MI patient
6 September 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources